FDA's first mRNA flu shot signals broader potential for RNA therapeutics
FDA approved a new mRNA-based seasonal flu vaccine for adults 50+ on Aug. 5, 2026, illustrating mRNA’s promise to accelerate drug development beyond vaccines; but two hurdles remain: the short cellular half-life of about one day and impurities like double-stranded RNA that can provoke immune responses. Ongoing work aims to reduce immune activation and extend durability through pseudouridine-like RNA modifications, cleaner production, and optimized sequences, enabling non-vaccine uses such as CRISPR-Cas9 mRNA therapies (e.g., liver-targeted treatments for hereditary transthyretin amyloidosis) and paving the way for a new generation of safer, longer-lasting mRNA therapeutics in coming years.